Bottom line
FPHAX vs ETHSX: the short answer
FPHAX (Pharmaceuticals Portfolio) and ETHSX (Eaton Vance Worldwide Health Sciences Fund) are quite different portfolios: only about 38% of their top holdings (by weight) are shared.
FPHAX is cheaper at 0.67% vs 1.18% — a difference of $51 a year per $10,000 invested.
Over five years, FPHAX returned +12.6% a year vs +5.3% for ETHSX (reporting dates differ).
ETHSX has a front-end sales load of up to 5.25%; the other does not.
Updated Nov 19, 2026
FPHAX vs ETHSX side by side
| FPHAX | ETHSX | |
|---|---|---|
| Type | Mutual fund | Mutual fund |
| Fund family | Fidelity | Morgan Stanley |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.67% | 1.18% |
| Annual cost per $10k | $67 | $118 |
| 10-yr cost on $10k (prospectus) | $835 | $1,911 |
| Max front load | — | 5.25% |
| 12b-1 fee | 0% | 0.25% |
| 1-yr return | +30.3% | −1.9% |
| 5-yr return (annualized) | +12.6% | +5.3% |
| 10-yr return (annualized) | +10.0% | +6.4% |
| Best quarter | +18.5% | +14.2% |
| Worst quarter | −13.6% | −12.1% |
| Net assets (fund) | $1.5B | $757.9M |
| Number of holdings | 57 | 42 |
| Portfolio turnover | 77% | 3% |
| Returns as of | Apr 30, 2026 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | FPHAX | ETHSX | Difference |
|---|---|---|---|
| 2024 | +9.4% | +3.5% | +5.9% |
| 2023 | +12.5% | +5.7% | +6.9% |
| 2022 | +1.0% | −9.4% | +10.4% |
| 2021 | +11.8% | +22.1% | −10.2% |
| 2020 | +11.1% | +13.0% | −2.0% |
| 2019 | +31.6% | +26.0% | +5.6% |
| 2018 | +5.8% | +6.0% | −0.2% |
| 2017 | +10.7% | +16.2% | −5.5% |
| 2016 | −16.3% | −14.9% | −1.4% |
Source: Fund prospectus bar charts
Holdings overlap
7 of FPHAX's top 25 holdings also appear in ETHSX's top 25.
| Holding | FPHAX | ETHSX |
|---|---|---|
| ELI LILLY and CO | 28.78% | 12.47% |
| MERCK and CO INC | 4.74% | 5.08% |
| Roche Holding Ag | 4.54% | 5.44% |
| Astrazeneca Plc | 4.22% | 6.24% |
| Gilead Sciences Inc | 3.97% | 3.34% |
| JOHNSON and JOHNSON | 3.77% | 6.45% |
| Royalty Pharma Plc | 2.67% | 1.58% |
Source: SEC Form N-PORT
FPHAX top 10
- ELI LILLY and CO — 28.78%
- Gsk Plc — 8.17%
- Viatris Inc — 5.45%
- Ucb Sa — 5.09%
- MERCK and CO INC — 4.74%
- Roche Holding Ag — 4.54%
- Legend Biotech Corp — 4.53%
- Astrazeneca Plc — 4.22%
- Elanco Animal Health Inc — 4.15%
- Jazz Pharmaceuticals Plc — 4.09%
ETHSX top 10
- Eli Lilly & Co — 12.47%
- AbbVie Inc — 6.46%
- Johnson & Johnson — 6.45%
- AstraZeneca PLC — 6.24%
- UnitedHealth Group Inc — 5.49%
- Roche Holding AG — 5.44%
- Merck & Co Inc — 5.08%
- Bristol-Myers Squibb Co — 4.25%
- Vertex Pharmaceuticals Inc — 3.38%
- Gilead Sciences Inc — 3.34%
FAQ
What is the difference between FPHAX and ETHSX?
Which is cheaper, FPHAX or ETHSX?
Should I own both FPHAX and ETHSX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.